66 related articles for article (PubMed ID: 7576031)
1. A seroepidemiologic study of HPV infection and incident cervical squamous intraepithelial lesions.
Strickler HD; Dillner J; Schiffman MH; Eklund C; Glass AG; Greer C; Scott DR; Sherman ME; Kurman RJ; Manos M
Viral Immunol; 1994; 7(4):169-77. PubMed ID: 7576031
[TBL] [Abstract][Full Text] [Related]
2. [Cervix uteri lesions and human papiloma virus infection (HPV): detection and characterization of DNA/HPV using PCR (polymerase chain reaction].
Serra H; Pista A; Figueiredo P; Urbano A; Avilez F; De Oliveira CF
Acta Med Port; 2000; 13(4):181-92. PubMed ID: 11155485
[TBL] [Abstract][Full Text] [Related]
3. Immune activation in cervical neoplasia: cross-sectional association between plasma soluble interleukin 2 receptor levels and disease.
Hildesheim A; Schiffman MH; Tsukui T; Swanson CA; Lucci J; Scott DR; Glass AG; Rush BB; Lorincz AT; Corrigan A; Burk RD; Helgesen K; Houghten RA; Sherman ME; Kurman RJ; Berzofsky JA; Kramer TR
Cancer Epidemiol Biomarkers Prev; 1997 Oct; 6(10):807-13. PubMed ID: 9332763
[TBL] [Abstract][Full Text] [Related]
4. Determinants of squamous intraepithelial lesions (SIL) on Pap smear: the role of HPV infection and of HIV-1-induced immunosuppression. DIANAIDS Collaborative Study Group.
Rezza G; Giuliani M; Branca M; Benedetto A; Migliore G; Garbuglia AR; D'Ubaldo C; Pezzotti P; Cappiello G; Pomponi Formiconi D; Suligoi B; Schiesari A; Ippolito G; Giacomini G
Eur J Epidemiol; 1997 Dec; 13(8):937-43. PubMed ID: 9476825
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for cervical neoplasia in Denmark.
Kjaer SK
APMIS Suppl; 1998; 80():1-41. PubMed ID: 9693662
[TBL] [Abstract][Full Text] [Related]
6. Evidence for at least two distinct groups of humoral immune reactions to papillomavirus antigens in women with squamous intraepithelial lesions.
Strickler HD; Schiffman MH; Eklund C; Glass AG; Scott DR; Sherman ME; Wacholder S; Kurman RJ; Manos MM; Schiller JT; Dillner J
Cancer Epidemiol Biomarkers Prev; 1997 Mar; 6(3):183-8. PubMed ID: 9138661
[TBL] [Abstract][Full Text] [Related]
7. Mucosal immunoglobulin-A and -G responses to oncogenic human papilloma virus capsids.
Sasagawa T; Rose RC; Azar KK; Sakai A; Inoue M
Int J Cancer; 2003 Apr; 104(3):328-35. PubMed ID: 12569556
[TBL] [Abstract][Full Text] [Related]
8. Cervical specimens collected in liquid buffer are suitable for both cytologic screening and ancillary human papillomavirus testing.
Sherman ME; Schiffman MH; Lorincz AT; Herrero R; Hutchinson ML; Bratti C; Zahniser D; Morales J; Hildesheim A; Helgesen K; Kelly D; Alfaro M; Mena F; Balmaceda I; Mango L; Greenberg M
Cancer; 1997 Apr; 81(2):89-97. PubMed ID: 9126136
[TBL] [Abstract][Full Text] [Related]
9. Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 58 and 59 virus-like particles in colombian women with invasive cervical cancer.
Combita AL; Bravo MM; Touzé A; Orozco O; Coursaget P
Int J Cancer; 2002 Feb; 97(6):796-803. PubMed ID: 11857357
[TBL] [Abstract][Full Text] [Related]
10. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection.
Carter JJ; Koutsky LA; Hughes JP; Lee SK; Kuypers J; Kiviat N; Galloway DA
J Infect Dis; 2000 Jun; 181(6):1911-9. PubMed ID: 10837170
[TBL] [Abstract][Full Text] [Related]
11. Antibodies prevalence against HPV-6b and -16 recombinant fusion proteins in Korean patients with cervical neoplasia.
Park SN; Yoon HS; Choi YK; Choe IS; Chung RP; Chee YH; Namkoong SE; Kim SJ; Park JS
J Obstet Gynaecol (Tokyo 1995); 1995 Dec; 21(6):609-17. PubMed ID: 8640473
[TBL] [Abstract][Full Text] [Related]
12. Human papillomavirus antibody responses among patients with incident cervical carcinoma.
Wang Z; Konya J; Avall-Lundkvist E; Sapp M; Dillner J; Dillner L
J Med Virol; 1997 Aug; 52(4):436-40. PubMed ID: 9260694
[TBL] [Abstract][Full Text] [Related]
13. Viral load of episomal and integrated forms of human papillomavirus type 33 in high-grade squamous intraepithelial lesions of the uterine cervix.
Khouadri S; Villa LL; Gagnon S; Koushik A; Richardson H; Matlashewski G; Roger M; Ferenczy AS; Franco EL; Coutlée F
Int J Cancer; 2007 Dec; 121(12):2674-81. PubMed ID: 17708553
[TBL] [Abstract][Full Text] [Related]
14. [Cancer of the cervix, papillomavirus, contraception and tobacco].
Thiry L; Vokaer R; Detremmerie O; De Schepper N; Herzog A; Bollen A
J Gynecol Obstet Biol Reprod (Paris); 1993; 22(5):477-86. PubMed ID: 8228010
[TBL] [Abstract][Full Text] [Related]
15. Human leukocyte antigen class I/II alleles and development of human papillomavirus-related cervical neoplasia: results from a case-control study conducted in the United States.
Hildesheim A; Schiffman M; Scott DR; Marti D; Kissner T; Sherman ME; Glass AG; Manos MM; Lorincz AT; Kurman RJ; Buckland J; Rush BB; Carrington M
Cancer Epidemiol Biomarkers Prev; 1998 Nov; 7(11):1035-41. PubMed ID: 9829713
[TBL] [Abstract][Full Text] [Related]
16. A population-based seroepidemiological study of cervical cancer.
Dillner J; Lenner P; Lehtinen M; Eklund C; Heino P; Wiklund F; Hallmans G; Stendahl U
Cancer Res; 1994 Jan; 54(1):134-41. PubMed ID: 8261434
[TBL] [Abstract][Full Text] [Related]
17. HPV 16 antibody prevalence in Jamaica and the United States reflects differences in cervical cancer rates.
Strickler HD; Kirk GD; Figueroa JP; Ward E; Braithwaite AR; Escoffery C; Drummond J; Goebel B; Waters D; McClimens R; Manns A
Int J Cancer; 1999 Jan; 80(3):339-44. PubMed ID: 9935171
[TBL] [Abstract][Full Text] [Related]
18. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women.
Strickler HD; Burk RD; Fazzari M; Anastos K; Minkoff H; Massad LS; Hall C; Bacon M; Levine AM; Watts DH; Silverberg MJ; Xue X; Schlecht NF; Melnick S; Palefsky JM
J Natl Cancer Inst; 2005 Apr; 97(8):577-86. PubMed ID: 15840880
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus cervical infection and associated risk factors in a region of Argentina with a high incidence of cervical carcinoma.
Tonon SA; Picconi MA; Zinovich JB; Liotta DJ; Bos PD; Galuppo JA; Alonio LV; Ferreras JA; Teyssié AR
Infect Dis Obstet Gynecol; 1999; 7(5):237-43. PubMed ID: 10524669
[TBL] [Abstract][Full Text] [Related]
20. Seroreactivity to HPV16 virus-like particles as a marker for cervical cancer risk in high-risk populations.
Nonnenmacher B; Kruger Kjaer S; Svare EI; Scott JD; Hubbert NL; van den Brule AJ; Kirnbauer R; Walboomers JM; Lowy DR; Schiller JT
Int J Cancer; 1996 Dec; 68(6):704-9. PubMed ID: 8980170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
